Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. FIgure S4 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
  1. Home
  2. Publications
  3. FIgure S4 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)

FIgure S4 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)

Authors:
  • CLChengxin Liu
    Chengxin Liu
  • YDYang Du
    Yang Du
  • DHDan Han
    Dan Han
  • BLBaosheng Li
    Baosheng Li
  • XLXiaomeng Liu
    Xiaomeng Liu
  • BFBingjie Fan
    Bingjie Fan
  • HSHongfu Sun
    Hongfu Sun
  • CFChengrui Fu
    Chengrui Fu
  • LXLongyu Xu
    Longyu Xu
  • TDTianyuan Dai
    Tianyuan Dai
  • WHWei Huang
    Wei Huang

Open Access
Publisher website
Google Scholar
  • 2 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/2326-6066.32541547
Abstract
Supplementary Figure 4. Comparison of immune dynamics between responders and non-responders.
Keywords
  • IMMUNOTHERAPY
  • CHECKPOINT BLOCKADE
  • COMBINATION IMMUNOTHERAPY
  • LUNG CANCER
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.